Intec Pharma reports safety trial success

Giora Carni  picture: Eyal Yitzhar

The way is now open for a Phase 3 trial of the company's Accordion Levodopa product.

Intec Pharma Ltd. (TASE: INTP), managed by Giora Carni, reported success today in the safety trial for the Accordion Levodopa Pill that the company is developing. The company's share price rose 9% following the announcement.

The Accordion Pill is a gastro-retentive delivery system designed to improve the performance of narrow absorption window drugs and poorly soluble drugs. Levodopa is a treatment for Parkinson's disease.

The trial ended in late March, but processing of the results took several weeks. The results show that the trial endpoints were fully achieved, and that further significant consolidation of the safety profile of the Accordion Pill was obtained. The trial, which was carried out on animals, lasted a year, and was conducted in accordance with US Food and Drug Administration (FDA) requirements.

"The successful conclusion of the safety trial, which represents part of requirements for the Phase 3 trial for the Accordion Levodopa Pill, is another significant step forward for the company towards the start of a Phase 3 trial on Parkinson's disease patients," the company's notification to the Tel Aviv Stock Exchange states. The company has already obtained FDA consent for the Accordion Levodopa product to be fast tracked for regulatory approval.

Published by Globes [online], Israel business news - - on June 17, 2014

© Copyright of Globes Publisher Itonut (1983) Ltd. 2013

Giora Carni  picture: Eyal Yitzhar
Giora Carni picture: Eyal Yitzhar
Twitter Facebook Linkedin RSS Newsletters גלובס Israel Business Conference 2018